<DOC>
	<DOCNO>NCT00286130</DOCNO>
	<brief_summary>In Patients metastatic colorectal cancer follow treatment first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab concern efficacy safety . The trial compare Folfiri + Cetuximab Folfox6 + Cetuximab concern efficacy safety first</brief_summary>
	<brief_title>Safety Efficacy Folfox6 + Cetuximab Versus Folfiri +Cetuximab Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The multicenter randomize phase II study enroll target approximately 150 first-line patient metastatic CRC . EGFR expression require study entry , however , EGFR status measure retrospectively . Patients randomize Arm A Arm B . Arm A : FOLFOX 6 combination cetuximab Arm B : FOLFIRI combination cetuximab . Both efficacy safety data collect . The investigator assess response treatment 6 week , 12 week thereafter every 12 week base image Following permanent treatment cessation ( stop study treatment ) patient followed-up .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Diagnosis histologically confirm adenocarcinoma colon rectum Metastatic colorectal carcinoma suitable curativeintent resection Availability tumor sample ( able willing provide tumor sample ) EGFR assessment Presence least one lesion measurable unidimensional CT scan MRI ( Target lesion ( ) must lie within irradiated area ) ECOG performance status &lt; 2 study entry Brain metastasis ( know suspect ) Previous chemotherapy metastatic CRC adjuvant therapy oxaliplatin irinotecan . Adjuvant therapy 5 FU derivative allow chemotherapy treatment free interval &gt; 6 month Surgery ( exclude diagnostic biopsy ) irritation within 4 week prior study entry Cocurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Any investigational agent ( ) within 4 week prior entry Previous exposure EGFRpathway target therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>FOLFOX 6</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>